<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03914755</url>
  </required_header>
  <id_info>
    <org_study_id>SGNTUC-015</org_study_id>
    <nct_id>NCT03914755</nct_id>
  </id_info>
  <brief_title>A Safety, Tolerability, and Pharmacokinetic Study of Tucatinib in Healthy Japanese and Caucasian Subjects</brief_title>
  <official_title>A Phase 1, Open Label, Safety, Tolerability, and Pharmacokinetic Study of Tucatinib (ONT-380) in Healthy Japanese and Caucasian Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seagen Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seagen Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to compare the pharmacokinetics (PK) and safety/tolerability of&#xD;
      tucatinib in healthy Japanese and Caucasian participants.&#xD;
&#xD;
      Three cohorts of healthy Japanese and Caucasian men and women will be admitted to the&#xD;
      Clinical Research Unit (CRU) and receive multiple oral doses of tucatinib over 14 days with&#xD;
      and without food.&#xD;
&#xD;
      Subjects will be in the study for up to 45 days, including the screening period.&#xD;
&#xD;
      Due to practical considerations, each cohort will be dosed sequentially (this is not a dose&#xD;
      escalation study).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 8, 2019</start_date>
  <completion_date type="Actual">August 4, 2019</completion_date>
  <primary_completion_date type="Actual">August 4, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed concentration (Cmax) of tucatinib</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of ONT-993</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of the maximum observed concentration (tmax) of tucatinib</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of ONT-993</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC from time 0 to the time of last quantifiable concentration (AUClast) of tucatinib</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of ONT-993</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC from time 0 to 12 hours postdose (AUC0-12hr) of tucatinib</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-12hr of ONT-993</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC from time 0 extrapolated to infinity (AUC0-inf) of tucatinib</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC from time 0 extrapolated to infinity (AUC0-inf) of ONT-993</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of AUC0-inf due to extrapolation (%AUCextrap) of tucatinib</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>%AUCextrap of ONT-993</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent total clearance (CL/F) of tucatinib</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent volume of distribution during the terminal phase (Vz/F) of tucatinib</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolite-to-parent molar ratio based on AUC (MRAUC) of ONT-993</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (AEs)</measure>
    <time_frame>17 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg twice daily on Days 1-13 and once daily on Day 14</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 mg twice daily on Days 1-13 and once daily on Day 14</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg twice daily on Days 1-13 and once daily on Day 14</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tucatinib</intervention_name>
    <description>Administered via oral tablet</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body mass index between 18 and 32 kg/m^2 and a total body weight between 50 and 100 kg&#xD;
&#xD;
          -  In good health, determined by no clinically significant findings from medical history,&#xD;
             physical examination, 12-lead electrocardiograms, vital signs measurements, or&#xD;
             clinical laboratory evaluations&#xD;
&#xD;
          -  Female subjects participating in the study will be of non-childbearing potential. Male&#xD;
             subjects will be surgically sterile for at least 90 days or will agree to use&#xD;
             contraception during the study and for 90 days after last dose of study drug.&#xD;
&#xD;
          -  Japanese subjects:&#xD;
&#xD;
               1. Must have been born in Japan&#xD;
&#xD;
               2. Must have 2 biological Japanese parents and 4 biological Japanese grandparents as&#xD;
                  confirmed by interview&#xD;
&#xD;
               3. Must have spent less than 10 years outside of Japan, and has no significant&#xD;
                  changes in lifestyle, including diet, since leaving Japan&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant history of metabolic, allergic, dermatological, hepatic, renal,&#xD;
             hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory,&#xD;
             endocrine, or psychiatric disorder&#xD;
&#xD;
          -  Current condition possibly affecting drug absorption&#xD;
&#xD;
          -  History of significant hypersensitivity, intolerance, or allergy to any drug compound,&#xD;
             food, or other substance&#xD;
&#xD;
          -  History of stomach or intestinal surgery or resection that would potentially alter&#xD;
             absorption or excretion of orally administered drugs&#xD;
&#xD;
          -  History of alcoholism or drug/chemical abuse within 2 years of check-in&#xD;
&#xD;
          -  History of regular alcohol consumption exceeding 7 drinks/week for female subjects or&#xD;
             14 drinks/week for male subjects&#xD;
&#xD;
          -  Positive hepatitis panel and/or positive human immunodeficiency (HIV) test&#xD;
&#xD;
          -  Liver function tests, serum creatinine, hemoglobin, or hematocrit values outside of&#xD;
             the normal reference range&#xD;
&#xD;
          -  Single 12-lead ECG demonstrating QTcF&gt;450 msec for males or &gt;470 msec for females&#xD;
&#xD;
          -  Participation in a clinical study involving administration of an investigational drug&#xD;
             in the past 30 days from last dose or 5 half-lives (whichever is longer)&#xD;
&#xD;
          -  Use of any products known to alter drug absorption, metabolism or elimination&#xD;
             processes, including St. John's wort and known strong inhibitors or inducers of CYP3A4&#xD;
             or CYP2C8, within 30 days&#xD;
&#xD;
          -  Use of or intention to use any prescription or nonprescription products, including&#xD;
             vitamins, minerals and herbal preparations within 14 days&#xD;
&#xD;
          -  Use of tobacco- or nicotine-containing products within 3 months&#xD;
&#xD;
          -  Receipt of blood products within 2 months&#xD;
&#xD;
          -  Donation of blood from 56 days before the Screening Visit, plasma from 2 weeks before&#xD;
             the Screening Visit or platelets from 6 weeks before the Screening Visit&#xD;
&#xD;
          -  Poor peripheral venous access&#xD;
&#xD;
          -  Have previously completed or withdrawn from this study or any other study&#xD;
             investigating tucatinib and have previously received the study drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Woolery, PharmD, BCOP</last_name>
    <role>Study Director</role>
    <affiliation>Seagen Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PAREXEL International, Early Phase Clinical Unit - Los Angeles</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>April 10, 2019</study_first_submitted>
  <study_first_submitted_qc>April 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2019</study_first_posted>
  <last_update_submitted>September 3, 2019</last_update_submitted>
  <last_update_submitted_qc>September 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tucatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

